

Supplementary Materials for
**Distinct roles of LARP1 and 4EBP1/2 in regulating translation and stability
of 5'TOP mRNAs**

Tobias Hochstoeger *et al.*

Corresponding author: Jeffrey A. Chao, jeffrey.chao@fmi.ch

Sci. Adv. **10**, eadi7830 (2024)
DOI: 10.1126/sciadv.adi7830

The PDF file includes:

Figs. S1 to S16
Table S2
Legends for tables S1, S3 to S6
Legends for movies S1 to S20

Other Supplementary Material for this manuscript includes the following:

Tables S1, S3 to S6
Movies S1 to S20

Fig. S1. Validation of transcription start site selection. Mapping of canonical and 5'TOP reporter transcription start sites (TSS) using cap-specific adaptor ligation. Sequencing results for single clones of each reporter are shown with the TeloPrime adaptor sequence joined to the start of the reporter 5'UTR. For the 5'TOP reporter, there is some variability in the precise cytosine in the +1 position, however, all sequenced clones initiate with a cytosine and contain a 5'TOP motif.

Fig. S2. mTORC1 signaling in canonical and 5'TOP mRNA cell lines treated with Torin1. Western blot analysis of mTORC1 signaling using a phosphorylation-specific antibody against 4EBP1. Upon Torin1 addition (250 nM, 1 hour), 4EBP1 is dephosphorylated, as seen by the lower migration size of 4EBP1 (left), and the disappearance of Pho-4EBP1^{Ser65} (right). Lines indicate cut membrane pieces probed with different mouse (magenta) and rabbit (green) antibodies, and imaged together using two-color fluorescent imaging. Brightness and contrast were individually adjusted for each antibody shown.

Fig. S3. Translation site intensities following global translation inhibition. (A) Quantification of translation site intensities after puromycin treatment (100 µg/ml, 5-30min). SunTag intensities are plotted for >400 mRNAs per condition overlaid with the mean ± SD. A cutoff of 1.5 (dotted line) was determined to distinguish translating from non-translating mRNAs. (B) Fraction of mRNAs undergoing translation after puromycin treatment. Values are plotted for each cell overlaid with the mean ± SD (≥87 cells per condition).

Fig. S4. Translation site intensities following ribosome run-off. (A) Quantification of translation site intensities after mTOR inhibition (250 nM Torin1, 1 hour) followed by translation inhibition (3 µg/ml Harringtonine, 10-30 min). SunTag intensities are plotted for >250 mRNAs per condition overlaid with the mean ± SD. (B) Fraction of mRNAs undergoing translation after mTOR inhibition (250 nM Torin1, 1 hour) followed by translation inhibition (Harringtonine 3 µg/ml, 10-30 min). Values are plotted for each cell overlaid with the mean ± SD (≥46 cells per condition).

Fig. S5. Single-molecule imaging of 5'TOP translational repression using additional mTOR inhibitors. (A) Quantification of translation site intensities of canonical and 5'TOP mRNAs in absence or presence of mTOR inhibitors Rapamycin (100 nM, 1 hour), PP242 (2.5 µM, 1 hour), or TAK228 (250 nM, 1 hour). SunTag intensities are plotted for all mRNAs overlaid with the mean

\pm SD (≥ 821 mRNAs per condition, $n=3$). **(B)** Fraction of mRNAs undergoing translation quantified per cell for canonical and 5'TOP reporter cell lines in absence or presence of Rapamycin (100 nM, 1 hour), PP242 (2.5 μ M, 1 hour), or TAK228 (250 nM, 1 hour). Values are plotted for each cell overlaid with the mean \pm SD (≥ 112 cells per condition, $n=3$). For statistics, unpaired t tests were performed, with statistical significance claimed when $p < 0.05$ (ns = not significant, * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$).

Fig. S6. Western blot analysis of mTORC1 activity in cells treated with additional mTOR inhibitors. To inhibit mTOR, cells were treated for 1 hour with Rapamycin (0.1 μ M, 1 μ M, 10 μ M), PP242 (2.5 μ M), or TAK228 (250 nM), and mTORC1 activity was measured using phosphorylation-specific antibodies against Pho-RPS6, Pho-S6K1, Pho-4EBP1^{Ser65}, and the shift in migration size of 4EBP1. In agreement with previous studies (31, 36), Rapamycin causes substrate-selective inhibition of mTORC1 in HeLa cells, inhibiting Pho-RPS6 and Pho-S6K1, but not Pho-4EBP1 independent of drug concentration.

Fig. S7. Validation of LARP1 knockout cell lines. **(A)** CRISPR-Cas9 editing strategy for deletion of LARP1 protein expression in canonical and 5'TOP mRNA cell lines. Two sgRNAs targeting exon 4 upstream of any domains of known function were used to ensure high editing efficiency in polyploid HeLa genome (sgRNA 1 taken from (5)). **(B)** Genotyping of canonical and 5'TOP KO single clonal cell lines used for single-molecule imaging (Fig. 2A, 2B, 2E), showing ~ 100 bp truncations of *LARP1* exon 4 resulting in frameshifting and premature termination codons. **(C)** Western Blot analysis of LARP1 protein expression in WT and LARP1 KO single clonal cell lines. Clones B5 and E6 were used for single-molecule imaging of the canonical and 5'TOP mRNAs respectively. Note the presence of a weak shorter band of LARP1 (highlighted with *) for some clones, indicating the presence of an in-frame truncated allele of *LARP1* in these clones (KD). **(D)** Western blot analysis of mTORC1 signaling in canonical and 5'TOP LARP1 KO cell lines used for single-molecule imaging. Upon 1 hour Torin1 (250 nM), mTORC1 targets are dephosphorylated, as shown with phosphorylation-specific antibodies for Pho-4EBP1^{Ser65}, Pho-S6K1 and Pho-RPS6. 4EBP1 dephosphorylation is also seen by the lower migration size of dephosphorylated 4EBP1. Lines indicate cut membrane pieces probed with different mouse (magenta) and rabbit (green) antibodies, and imaged together using two-color fluorescent imaging. Brightness and contrast were individually adjusted for each antibody shown.

Fig. S8. Single-molecule imaging of translation in LARP1 KO and LARP1/1B KO cell lines.

(A) Representative images of LARP1 KO cell lines expressing canonical and 5'TOP mRNAs (MCP-Halo foci, magenta) undergoing translation (scFv-GFP foci, green) in the absence or presence of mTOR inhibitor Torin 1 (250 nM, 1 hour). (B) Representative images of LARP1/1B KO cell lines expressing canonical and 5'TOP mRNAs (MCP-Halo foci, magenta) undergoing translation (scFv-GFP foci, green) in absence or presence of mTOR inhibitor Torin 1 (250 nM, 1 hour). Scale bars = 5 μ m.

Fig. S9. Validation of LARP1/1B KO cell lines. (A) CRISPR-Cas9 editing strategy for *LARP1B* gene locus, using two sgRNAs targeting exon 4 of *LARP1B* upstream of any domain of known function (sgRNA 1 taken from (37)). (B) Validation of ~100bp truncations of *LARP1B*, using cDNA generated from total RNA extracted from LARP1/1B KO canonical and 5'TOP mRNA cell lines used for single-molecule imaging. (C) Genotyping of canonical and 5'TOP LARP1/1B KO clones used for single-molecule imaging (Fig. 2C-E), showing ~100 bp truncations of *LARP1B* exon 4 resulting in frameshifting and premature termination codons. (D) Western blot analysis of mTORC1 signaling in canonical and 5'TOP LARP1/1B KO cell lines used for single-molecule imaging. Upon 1 hour Torin1 (250 nM), mTORC1 targets are dephosphorylated, as shown with phosphorylation-specific antibodies for Pho-4EBP1^{Ser65}, Pho-S6K1 and Pho-RPS6, and the shift of 4EBP1 migration size. Lines indicate cut membrane pieces probed with different mouse (magenta) and rabbit (green) antibodies, and imaged together using two-color fluorescent imaging. Brightness and contrast were individually adjusted for each antibody shown.

Fig. S10. Translation of canonical mRNAs under long-term Torin1 treatment. (A) Quantification of SunTag translation site intensities for canonical mRNAs in WT cells after 24 hours Torin1 treatment (250 nM). SunTag intensities are plotted for 420 mRNAs overlaid with the mean \pm SD. (B) Fraction of mRNAs undergoing translation quantified per cell after 24 hours Torin1 treatment (250 nM). Individual values are plotted overlaid with the mean \pm SD of 37 cells.

Fig. S11. Validation of shRNA-mediated knockdown of 4EBP1/2 proteins. (A) Western blot analysis of stable knockdown of 4EBP1/2 proteins in canonical and 5'TOP mRNA cell lines with

WT LARP1 (left) or LARP1/1B KO (right). Depletion of 4EBP1 and 4EBP2 proteins was analyzed in mTOR active cells with 4EBP1 and 4EBP2 antibodies. **(B)** Quantification of knockdown efficiency in canonical and 5'TOP mRNA cell lines with WT LARP1. Total lysate was loaded in amounts of 10, 5, and 2.5 μ g to test antibody linearity, and semi-quantitative estimates of knockdown efficiency were calculated (4EBP1/2 KD/WT) for both cell lines. **(C)** Western blot analysis of mTORC1 signaling in 4EBP1/2 KD cell lines with WT LARP1 (left) or LARP1/1B KO (right). Upon 1 hour Torin1, RPS6 became dephosphorylated as seen by the decreased signal for Phospho-RPS6. 4EBP1 and 4EBP2 are detected at low levels. **(D)** Western blot analysis of mTORC1 signaling in 4EBP1/2 KD reporter cell lines with WT LARP1 (left) or LARP1/1B KO (right). Upon 1 hour Torin1 (250 nM), residual 4EBP1 becomes dephosphorylated as seen by the disappearance of Phospho-4EBP1^{Ser65}. Lines indicate cut membrane pieces probed with different mouse (magenta) and rabbit (green) antibodies, and imaged together using two-color fluorescent imaging. Brightness and contrast were individually adjusted for each antibody shown.

Fig. S12. Single-molecule imaging of translation in 4EBP1/2 KD, 4EBP1/2 KD_ LARP1/1B KO cell lines. **(A)** Representative images of canonical and 5'TOP reporter mRNAs in 4EBP1/2 KD cells (MCP-Halo foci, magenta) undergoing translation (scFv-GFP foci, green) in absence or presence of mTOR inhibitor Torin 1 (250 nM, 1 hour). **(B)** Representative images of canonical and 5'TOP mRNAs in 4EBP1/2 KD_ LARP1/1B KO cells (MCP-Halo foci, magenta) undergoing translation (scFv-GFP foci, green) in absence or presence of mTOR inhibitor Torin 1 (250 nM, 1 hour). Scale bars = 5 μ m.

Fig. S13. Mutation of 5'TOP motif is sufficient to relieve 5'TOP translational repression of RPL32 5'TOP mRNAs. Single-molecule imaging of 5'TOP reporter mRNAs with the 5'TOP motif mutated (Δ 5'TOP), or the 5'TOP motif and downstream pyrimidine-rich translational element mutated (Δ 5'TOP/PRTE). **(A)** Full-length RPL32 5'UTR contained in the 5'TOP reporter mRNA aligned against the mutated RPL32 5'UTRs contained in the Δ 5'TOP and Δ 5'TOP/PRTE reporter mRNAs. The mutated 5'TOP motif sequence matches the cap-adjacent sequence of the canonical reporter mRNA (+1 - +11). **(B)** Quantification of translation site intensities of Δ 5'TOP and Δ 5'TOP/PRTE mRNAs in absence or presence of Torin1 (250 nM, 1 hour). SunTag intensities are plotted for all mRNAs overlaid with the mean \pm SD (\geq 628 mRNAs per condition, n=3). **(C)** Fraction of mRNAs undergoing translation quantified per cell for Δ 5'TOP and Δ 5'TOP/PRTE mRNAs

in absence or presence of Torin1 (250 nM, 1 hour). Values are plotted for each cell overlaid with the mean \pm SD (≥ 110 cells per condition, $n=3$). **(D)** Quantification of translation site intensities of $\Delta 5'$ TOP mRNAs in LARP1 KO cells \pm Torin1 (250 nM, 1 hour). SunTag intensities are plotted for all mRNAs overlaid with the mean \pm SD (≥ 730 mRNAs per condition, $n=3$). **(E)** Fraction of translating mRNAs per cell for $\Delta 5'$ TOP mRNAs in LARP1 KO cells \pm Torin1 (250 nM, 1 hour). Values are plotted for each cell overlaid with the mean \pm SD (≥ 127 cells per condition, $n=3$). **(F)** Quantification of translation site intensities of $\Delta 5'$ TOP mRNAs in 4EBP1/2 KD cells \pm Torin1 (250 nM, 1 hour). SunTag intensities are plotted for all mRNAs overlaid with the mean \pm SD (≥ 1598 mRNAs per condition, $n=3$). **(G)** Fraction of translating mRNAs per cell for $\Delta 5'$ TOP mRNAs in 4EBP1/2 KD cells \pm Torin1 (250 nM, 1 hour). Values are plotted for each cell overlaid with the mean \pm SD (≥ 235 cells per condition, $n=3$). For statistics, unpaired t tests were performed, with statistical significance claimed when $p < 0.05$ (ns = not significant, * = $p < 0.05$, ** = $p < 0.01$). **(H)** Overview of the mean fraction of translating mRNAs per cell for canonical, 5'TOP, $\Delta 5'$ TOP, and $\Delta 5'$ TOP/PRTE mRNAs in absence or presence of 1 hour Torin1, listed for WT cells, LARP1 KO cells, and 4EBP1/2 KD cells.

Fig. S14. Western blot validation of LARP1 KO and 4EBP1/2 KD for $\Delta 5'$ TOP and $\Delta 5'$ TOP/PRTE cell lines. **(A)** Western blot analysis of LARP1 protein expression in wildtype (WT) and LARP1 CRISPR-Cas9 edited single clonal cell lines, confirming full loss of LARP1 protein expression. mTORC1 signaling is unperturbed in the LARP1 KO cells, as shown with phosphorylation-specific antibodies for Pho-4EBP1^{Ser65}, Pho-S6K1 and Pho-RPS6. **(B)** Western blot analysis of 4EBP1/2 protein levels in WT and stable shRNA-mediated knockdown cells, confirming high knockdown efficiency. mTORC1 signaling of S6K1 and RPS6 phosphorylation is unperturbed in the 4EBP1/2 KD cells, as shown with phosphorylation-specific antibodies for Pho-S6K1 and Pho-RPS6. Lines indicate cut membrane pieces probed with different mouse (magenta) and rabbit (green) antibodies, and imaged together using two-color fluorescent imaging. Brightness and contrast were individually adjusted for each antibody shown.

Fig. S15. Validation of RNA-seq results for select 5'TOP mRNAs by smFISH. **(A)** Representative smFISH images of WT and LARP1 KO cells, showing smFISH spots for endogenous 5'TOP (*RPL5*, *RPL11*, *RPL32*: green, quasar-570 dye) and non-5'TOP control mRNAs (*MYC*: magenta, atto-633 dye). Scale bars = 5 μ m. **(B)** Quantification of 5'TOP (*RPL5*, *RPL11*, *RPL32*), and non-

5'TOP (*MYC*) mRNA spots per cell for WT, 4EBP1/2 KD, and LARP1 KO cell lines used in Fig. 4A-C. The mean of canonical and 5'TOP reporter cell lines are shown as biological replicates (n=2). (C) Mean fold changes of *RPL5*, *RPL11*, *RPL32*, and *MYC* mRNA levels (mutant/WT) as determined by smFISH or RNA-seq (Fig. 4A-C). For all 5'TOP mRNAs tested, smFISH recapitulates the selective decrease of 5'TOP mRNA levels measured for LARP1 KO cells.

Fig. S16. Global analysis of mRNA half-lives determined by SLAM-seq. (A) Distribution of RNA half-lives estimated from SLAM-seq data for WT and LARP1 KO cell lines. Values are plotted with the median and interquartile range. (B) List of 5'TOP mRNAs from SLAMseq data, ranked by log₂ fold change (LFC). The sequence of the first 14 nt of the 5'UTR containing the 5'TOP motif (*RPL23A* 5'UTR: 12 nt), the length of the 5'TOP motif, and presence or absence of a downstream pyrimidine-rich translational element (PRTE) within the 5'UTR is shown.

	TeloPrime Fwd Primer	RPL32 5'UTR
<i>Clone 1</i>	TGGATTGATATGTAATACGACTCACTATAG	CCTCTCTTCCTCGGCGCTGC...
<i>Clone 2</i>	TGGATTGATATGTAATACGACTCACTATAG	CCTCTCTTCCTCGGCGCTGC...
<i>Clone 3</i>	TGGATTGATATGTAATACGACTCACTATAG	CTCTCTTCCTCGGCGCTGC...
<i>Clone 4</i>	TGGATTGATATGTAATACGACTCACTATAG	CTCTCTTCCTCGGCGCTGC...
<i>Clone 5</i>	TGGATTGATATGTAATACGACTCACTATAG	CCTCTCTTCCTCGGCGCTGC...
<i>Clone 6</i>	TGGATTGATATGTAATACGACTCACTATAG	CCTCTCTTCCTCGGCGCTGC...
<i>Clone 7</i>	TGGATTGATATGTAATACGACTCACTATAG	CCTCTCTTCCTCGGCGCTGC...
<i>Clone 8</i>	TGGATTGATATGTAATACGACTCACTATAG	CTCTCTTCCTCGGCGCTGC...
<i>Clone 9</i>	TGGATTGATATGTAATACGACTCACTATAG	CCTCTCTTCCTCGGCGCTGC...
<i>Clone 10</i>	TGGATTGATATGTAATACGACTCACTATAG	CCTCTCTTCCTCGGCGCTGC...

	TeloPrime Fwd Primer	Canonical 5'UTR
<i>Clone 1</i>	TGGATTGATATGTAATACGACTCACTATAG	AGATCGCCTGGAGCAATTCC...
<i>Clone 2</i>	TGGATTGATATGTAATACGACTCACTATAG	AGATCGCCTGGAGCAATTCC...
<i>Clone 3</i>	TGGATTGATATGTAATACGACTCACTATAG	AGATCGCCTGGAGCAATTCC...
<i>Clone 4</i>	TGGATTGATATGTAATACGACTCACTATAG	AGATCGCCTGGAGCAATTCC...
<i>Clone 5</i>	TGGATTGATATGTAATACGACTCACTATAG	AGATCGCCTGGAGCAATTCC...
<i>Clone 6</i>	TGGATTGATATGTAATACGACTCACTATAG	AGATCGCCTGGAGCAATTCC...
<i>Clone 7</i>	TGGATTGATATGTAATACGACTCACTATAG	AGATCGCCTGGAGCAATTCC...
<i>Clone 8</i>	TGGATTGATATGTAATACGACTCACTATAG	AGATCGCCTGGAGCAATTCC...
<i>Clone 9</i>	TGGATTGATATGTAATACGACTCACTATAG	AGATCGCCTGGAGCAATTCC...

Fig. S1




Fig. S2




Fig. S3





Fig. S5




Fig. S6



Fig. S7





Fig. S8




A**B****C****D**

Fig. S9




Fig. S10







Fig. S11





Fig. S12








Fig. S13

A**B****Fig. S14**



C

mRNA	Cell line	smFISH fold change (mutant/WT)	RNAseq fold change (mutant/WT)
<i>RPL5</i>	4EBP1/2 KD	1.04	1.10
	LARP1 KO	0.69	0.67
<i>RPL11</i>	4EBP1/2 KD	0.89	1.04
	LARP1 KO	0.49	0.52
<i>RPL32</i>	4EBP1/2 KD	1.04	0.93
	LARP1 KO	0.70	0.56
<i>MYC</i>	4EBP1/2 KD	0.92	1.11
	LARP1 KO	0.92	1.20

Fig. S15





Fig. S16

Supplementary tables:

Tables S1, S3-S6 are provided as separate files.

Table S1. RNA-seq results of LARP1 KO cells compared to WT cells. Differential gene expression (log₂ FC) was calculated with the Bioconductor package edgeR, using an expression cutoff of log₂ CPM \geq 1 to exclude low confidence transcripts, and using gene type annotation to exclude pseudogenes.

Table S2. Reference list of 5'TOP mRNAs. Absence (0) or presence (1) of a putative pyrimidine-rich translational element is listed.

gene name	PRTE	gene name	PRTE	gene name	PRTE	gene name	PRTE
<i>EEF1A1</i>	0	<i>RPL13A</i>	0	<i>RPL36A</i>	1	<i>RPS18</i>	0
<i>EEF1B2</i>	1	<i>RPL14</i>	1	<i>RPL37</i>	1	<i>RPS19</i>	0
<i>EEF1D</i>	1	<i>RPL15</i>	1	<i>RPL37A</i>	1	<i>RPS2</i>	1
<i>EEF1G</i>	1	<i>RPL17</i>	1	<i>RPL38</i>	1	<i>RPS20</i>	1
<i>EEF2</i>	1	<i>RPL18</i>	0	<i>RPL39</i>	1	<i>RPS21</i>	0
<i>EIF2A</i>	0	<i>RPL18A</i>	1	<i>RPL3L</i>	0	<i>RPS23</i>	0
<i>EIF2S3</i>	0	<i>RPL19</i>	0	<i>RPL4</i>	1	<i>RPS24</i>	0
<i>EIF3A</i>	1	<i>RPL21</i>	0	<i>RPL41</i>	1	<i>RPS25</i>	0
<i>EIF3E</i>	0	<i>RPL22</i>	1	<i>RPL5</i>	1	<i>RPS26</i>	0
<i>EIF3F</i>	0	<i>RPL22L1</i>	0	<i>RPL6</i>	1	<i>RPS27</i>	0
<i>EIF3H</i>	0	<i>RPL23</i>	1	<i>RPL7</i>	1	<i>RPS27A</i>	1
<i>EIF3K</i>	0	<i>RPL23A</i>	0	<i>RPL7A</i>	0	<i>RPS28</i>	0
<i>EIF3L</i>	0	<i>RPL24</i>	0	<i>RPL8</i>	1	<i>RPS29</i>	0
<i>EIF4A2</i>	0	<i>RPL26</i>	0	<i>RPL9</i>	1	<i>RPS3</i>	0
<i>EIF4B</i>	1	<i>RPL27</i>	1	<i>RPLP0</i>	1	<i>RPS3A</i>	1
<i>FAU</i>	0	<i>RPL27A</i>	0	<i>RPLP1</i>	0	<i>RPS4X</i>	1
<i>GNB2L1</i>	1	<i>RPL28</i>	0	<i>RPLP2</i>	1	<i>RPS4Y1</i>	0
<i>HNRNPA1</i>	1	<i>RPL29</i>	1	<i>RPS10</i>	1	<i>RPS4Y2</i>	0
<i>NAP1L1</i>	1	<i>RPL3</i>	0	<i>RPS11</i>	1	<i>RPS5</i>	1
<i>PABPC1</i>	1	<i>RPL30</i>	0	<i>RPS12</i>	0	<i>RPS6</i>	1
<i>RACK1</i>	0	<i>RPL31</i>	1	<i>RPS13</i>	0	<i>RPS7</i>	0
<i>RPL10</i>	1	<i>RPL32</i>	1	<i>RPS14</i>	1	<i>RPS8</i>	1
<i>RPL10A</i>	0	<i>RPL34</i>	1	<i>RPS15</i>	0	<i>RPS9</i>	1
<i>RPL11</i>	0	<i>RPL35</i>	0	<i>RPS15A</i>	1	<i>RPSA</i>	0
<i>RPL12</i>	1	<i>RPL35A</i>	0	<i>RPS16</i>	0	<i>TPT1</i>	1
<i>RPL13</i>	1	<i>RPL36</i>	1	<i>RPS17</i>	0	<i>VIM</i>	1

Table S3. RNA-seq results of 4EBP1/2 KD cells compared to WT cells. An expression cutoff of $\log_2 \text{CPM} \geq 1$ was used to exclude low confidence transcripts, and gene type annotation to exclude pseudogenes.

Table S4. SLAM-seq results of LARP1/1B KO cells compared to WT cells. Low confidence half-life estimates were excluded using a Rsquared threshold of >0.75 in all conditions, and pseudogenes were excluded using gene type annotation.

Table S5. Reagent list.

Table S6. smFISH probe sequences.

Supplementary movies:

Movies are provided as separate files. Scale bars = 5 μ m.

Movie S1. Translation of canonical mRNAs in WT cells.

Movie S2. Translation of canonical mRNAs in WT cells treated with 1 hour Torin1.

Movie S3. Translation of 5'TOP mRNAs in WT cells.

Movie S4. Translation of 5'TOP mRNAs in WT cells treated with 1 hour Torin1.

Movie S5. Translation of canonical mRNAs in LARP1 KO cells.

Movie S6. Translation of canonical mRNAs in LARP1 KO cells treated with 1 hour Torin1.

Movie S7. Translation of 5'TOP mRNAs in LARP1 KO cells.

Movie S8. Translation of 5'TOP mRNAs in LARP1 KO cells treated with 1 hour Torin1.

Movie S9. Translation of canonical mRNAs in LARP1/1B KO cells.

Movie S10. Translation of canonical mRNAs in LARP1/1B KO cells treated with 1 hour Torin1.

Movie S11. Translation of 5'TOP mRNAs in LARP1/1B KO cells.

Movie S12. Translation of 5'TOP mRNAs in LARP1/1B KO cells treated with 1 hour Torin1.

Movie S13. Translation of canonical mRNAs in 4EBP1/2 KD cells.

Movie S14. Translation of canonical mRNAs in 4EBP1/2 KD cells treated with 1 hour Torin1.

Movie S15. Translation of 5'TOP mRNAs in 4EBP1/2 KD cells.

Movie S16. Translation of 5'TOP mRNAs in 4EBP1/2 KD cells treated with 1 hour Torin1.

Movie S17. Translation of canonical mRNAs in 4EBP1/2 KD_LARP1/1B KO cells.

Movie S18. Translation of canonical mRNAs in 4EBP1/2 KD_LARP1/1B KO cells treated with 1 hour Torin1.

Movie S19. Translation of 5'TOP mRNAs in 4EBP1/2 KD_LARP1/1B KO cells.

Movie S20. Translation of 5'TOP mRNAs in 4EBP1/2 KD_LARP1/1B KO cells treated with 1 hour Torin1.